Cellyan Biotechnology (HKPD) Operating Leases (2024 - 2025)

Cellyan Biotechnology (HKPD) reported Operating Leases of $129713.0 for Q3 2025, down 35.39% year-over-year from $200759.0 in Q3 2024, and up 1922.97% quarter-over-quarter from $6412.0 in Q1 2025.

Cellyan Biotechnology (HKPD) Operating Leases (2024 - 2025) Analysis & Trends

Cellyan Biotechnology (HKPD) has 2 years of Operating Leases data on file, last reported at $129713.0 in Q3 2025.

  • Operating Leases for Q3 2025 came in at $129713.0, down 35.39% year-over-year; the trailing twelve-month figure through Sep 2025 was $129713.0 (down 35.39% YoY), and the FY2025 annual result was $6412.0, down 94.56% from the prior year.
  • Operating Leases grew to $129713.0 in Q3 2025 per HKPD's latest filing, from $6412.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $200759.0 in Q3 2024 and troughed at $6412.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Akso Health 2,315,158.81 Bn 2,315,158.63 Bn -
2 Mckesson 92.76 Bn 89.18 Bn 4.04 Bn
3 Cencora 52.82 Bn 50.83 Bn 3.59 Bn
4 Cardinal Health 52.17 Bn 48.39 Bn 2.50 Bn
5 Henry Schein 9.19 Bn 9.71 Bn 1.07 Bn
6 Accendra Health 246.88 Mn -90.00 Mn 312.39 Mn
7 Edap Tms 161.92 Mn 146.92 Mn 8.15 Mn
8 111 107.47 Mn 25.61 Mn 23.58 Mn
9 Cosmos Health 9.42 Mn 7.26 Mn 1.38 Mn
10 Cellyan Biotechnology 5.69 -2.48 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 129,713.00
Mar 31, 2025 6,412.00
Sep 30, 2024 200,759.00
Mar 31, 2024 117,836.00